Suh Jungyo, Jung Jae Hyun, Jeong Chang Wook, Kwak Cheol, Kim Hyeon Hoe, Ku Ja Hyeon
Department of Urology, Seoul National University College of Medicine, Seoul, South Korea.
Department of Urology, Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, South Korea.
Front Oncol. 2019 Dec 16;9:1365. doi: 10.3389/fonc.2019.01365. eCollection 2019.
We performed a study-level meta-analysis to summarize the current evidence on the correlation between pretreatment neutrophil-to-lymphocyte ratios (NLR) and oncological outcomes in each type of management for urothelial carcinoma. All articles published until February 2017 in PubMed, Scopus, and EMBASE database were collected and reviewed. The current evidence on correlations between pretreatment NLR and oncological outcomes in each type of management for urothelial carcinoma, including transurethral resection of bladder tumor (TURBT), radical cystectomy (RCx), chemotherapy (CTx), and nephroureterectomy (NUx), were summarized. Thirty-eight studies containing clinical information on 16,379 patients were analyzed in this study. Pooled hazard ratios (HR) and odds ratios (OR) with 95% confidence intervals were calculated after weighing each study. Heterogeneity among the studies and publication bias were assessed. Pretreatment NLR was significantly associated with muscle invasiveness (OR: 4.27), recurrence free survival (RFS, HR: 2.32), and progression-free survival (PFS, HR: 2.45) in TURBT patients. In the RCx patients, high NLR was negatively associated with both disease status (extravesical extension and lymph-node positivity, OR: 1.14 and 1.43, respectively) and oncological outcomes [overall survival (OS), PFS], and cancer specific survival (CSS, HR: 1.18, 1.12, and 1.35, respectively). Pretreatment NLR was negatively correlated with pathologic downstaging (OR: 0.79) and positively correlated with PFS (HR: 1.30) and OS (HR: 1.44) in CTx patients. For patients who underwent NUx, pretreatment NLR was significantly associated with OS (HR: 1.72), PFS (HR: 1.63), and CSS (HR: 1.68). Pretreatment NLR is a useful biomarker for disease aggressiveness, oncological outcome, and treatment response in the management of patients with urothelial carcinoma. More evidence is needed to clarify these results.
我们进行了一项研究水平的荟萃分析,以总结目前关于尿路上皮癌每种治疗方式中治疗前中性粒细胞与淋巴细胞比值(NLR)与肿瘤学结局之间相关性的证据。收集并回顾了截至2017年2月在PubMed、Scopus和EMBASE数据库中发表的所有文章。总结了目前关于尿路上皮癌每种治疗方式(包括经尿道膀胱肿瘤切除术(TURBT)、根治性膀胱切除术(RCx)、化疗(CTx)和肾输尿管切除术(NUx))中治疗前NLR与肿瘤学结局之间相关性的证据。本研究分析了38项包含16379例患者临床信息的研究。在对每项研究进行加权后,计算了合并风险比(HR)和比值比(OR)以及95%置信区间。评估了研究之间的异质性和发表偏倚。在TURBT患者中,治疗前NLR与肌肉浸润性(OR:4.27)、无复发生存期(RFS,HR:2.32)和无进展生存期(PFS,HR:2.45)显著相关。在RCx患者中,高NLR与疾病状态(膀胱外扩展和淋巴结阳性,OR分别为1.14和1.43)和肿瘤学结局[总生存期(OS)、PFS]以及癌症特异性生存期(CSS,HR分别为1.18、1.12和1.35)均呈负相关。在CTx患者中,治疗前NLR与病理降期呈负相关(OR:0.